Sun Pharmaceutical Industries today announced settlement of patent litigation for generic Revlimid (lenalidomide) in the US.
Sun Pharmaceutical Industries along with one of its wholly owned subsidiaries today announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid (lenalidomide capsules) in the US.
Pursuant to the terms of the settlement, Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, will grant Sun Pharmaceutical Industries, a license to Celgene Corporation's patents required to manufacture and sell [subject to United States Food and Drug Administration (USFDA) approval] certain limited quantity of generic lenalidomide capsules in the United States beginning on a confidential date that is sometime after March 2022.
In addition, the license will also allow Sun Pharmaceutical Industries to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning on 31 January 2026.
As a result of the settlement, all Hatch-Waxman litigation between Sun Pharmaceutical Industries and Celgene Corporation, regarding the Revlimid (lenalidomide capsules) patents, will be dismissed. As per the exchange filing on the bourses, additional details regarding the settlement are confidential and the agreement is subject to customary regulatory approvals.
Shares of Sun Pharmaceutical Industries are trading lower by 0.34% at Rs 669 on BSE. The stock hovered in the range of Rs 668.50 and Rs 679.60 so far.
The announcement was made before trading hours yesterday, 22 June 2021.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU